Obesity medicine could alter the field of orthopedics in 2025, as GLP-1s like Ozempic and Wegovy can help patients lose weight, making them candidates for procedures they previously could not receive, ...

FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...

Havas released its latest trend intelligence report Superwomen at the 2025 Consumer Electronics Showcase this week, delving ...

Vancouver-based Aspect Biosystems has raised a $115-million USD ($165 million CAD) Series B round to realize its ambitions of ...

Popular medications, such as Ozempic, Mounjaro and Wegovy, are known as GLP-1 agonists as they mimic the natural GLP-1s ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Putting tariffs on Denmark unless it cedes the island of Greenland could hurt access to a few key products, including popular ...

Consumer-driven innovation, evolving dairy habits and target campaigns focused on value, convenience and sustainability are ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Users of GLP-1 drugs in the US cut their grocery spending by an average of 5.5% in the six months after taking the medication, a study shows.

For Robert F. Kennedy Jr., the activist whom President-elect Donald Trump will nominate to serve as the secretary of health and human services, the solution to obesity in America – now at 40% of ...